Simvastatin Attenuates Areca Nut Extract-Induced Subdermal Fibrosis in Mice by Targeting TGF-β Signaling Pathways

Area of Science:

• Oral pathology
• Pharmacology
• Fibrosis research

Background:

• Oral submucous fibrosis (OSMF) is a potentially malignant oral disorder characterized by oral mucosa fibrosis.
• Transforming growth factor-beta (TGF-β) signaling pathways and areca nut extract (ANE) are implicated in OSMF development.
• Simvastatin exhibits anti-fibrotic properties, but its efficacy in OSMF is not well-established.

Purpose of the Study:

• To investigate the therapeutic potential of simvastatin in an areca nut extract (ANE)-induced oral submucous fibrosis (OSMF) mouse model.
• To evaluate the effects of simvastatin on fibrosis markers and collagen deposition in ANE-treated mice.
• To assess simvastatin's impact on fibrosis-related protein expression.

Main Methods:

• BALB/c mice were treated with ANE and/or simvastatin across different time points.
• Histopathological examination and staining were used to assess skin thickness and collagen deposition.
• Western blot analysis was performed to measure fibrosis-related protein expression (CTGF, α-SMA).

Main Results:

• ANE treatment significantly increased skin thickness and collagen deposition compared to controls.
• Combined ANE and simvastatin administration notably reduced skin thickness and collagen deposition.
• Simvastatin suppressed the expression of fibrosis markers CTGF and α-SMA in ANE-induced fibrosis.

Conclusions:

• Simvastatin demonstrates potential therapeutic effects against ANE-induced subdermal fibrosis.
• These findings support further research into simvastatin as a treatment for OSMF.
• The study provides a basis for potential future clinical applications of simvastatin in managing OSMF.